In a recent transaction, Sheena Jonathan, co-founder of Natera, Inc. (NASDAQ:NTRA), a leader in medical laboratory services, sold a total of $283,794 worth of company stock. The sales took place on May 10, 2024, with the share prices for these transactions ranging from $103.06 to $107.48.
The transactions were executed in multiple batches, with shares being sold at various prices within the provided range. The largest single batch included the sale of 990 shares at an average price of $104.60, while the smallest batch consisted of 90 shares sold at $107.48 each. Other notable sales included 660 shares at an average price of $105.51 and 611 shares at $106.32 per share.
Following these transactions, Jonathan's direct ownership in Natera stands at 319,061 shares. It should be noted that an additional 138,164 shares are held indirectly through two trusts for the benefit of Jonathan's minor children, over which Jonathan disclaims beneficial ownership.
These sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. This plan had been adopted by Jonathan on December 12, 2023.
Investors and followers of Natera, Inc. should be aware of these transactions as part of their ongoing monitoring of insider activity within the company.
InvestingPro Insights
As investors evaluate the recent insider transactions at Natera, Inc. (NASDAQ:NTRA), it's essential to consider the company's current financial health and market performance. Natera's market capitalization, as of the latest data, stands at a robust $11.68 billion. Despite not offering dividends, the company has demonstrated a significant return over various periods, including a 103.97% return over the past year and an impressive 125.27% return over the last six months, indicating a strong bullish trend in its stock price.
The company's growth trajectory is also reflected in its revenue figures, with a notable year-over-year revenue growth of 31.99% in the last twelve months as of Q4 2023. This growth was even more pronounced in the most recent quarter, with a quarterly revenue growth of 43.2%. However, it's important to note that analysts do not anticipate Natera will be profitable this year, and the company has not been profitable over the last twelve months. The P/E ratio stands at -29.6, reflecting the market's expectation of future earnings potential despite current losses.
InvestingPro Tips highlight that while Natera's stock is trading near its 52-week high, with a price percentage of 97.5% of that peak, the RSI suggests the stock is in overbought territory. Additionally, the company's Price / Book multiple is high at 16.82, which could suggest that the stock is valued richly in terms of its net asset value. Investors considering Natera's stock may want to explore these dynamics further, and can find more detailed analysis and tips on InvestingPro, with a total of 14 additional tips available to help inform their investment decisions.
Interested investors can take advantage of an exclusive offer to enrich their investment strategy with a 10% discount on a yearly or biyearly Pro and Pro+ subscription using coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.